Table 2.

Characteristics of patients undergoing laparoscopic liver resection

History of laparotomy by midline incision	32/43	(76.1%)
Colostomy	4/32	(12.5%)
More than two laparotomies	3/32	(9.4%)
Preoperative chemotherapy (n = 14)
mFOLFOX6 + bevacizumab	8
mFOLFOX6	4
FOLFOX4 + bevacizumab	1
FOLFIRI + bevacizumab	1
Median cycle number (course)	7.2 ± 2.4
Indications for preoperative chemotherapy
Received chemotherapy in other institution	7
Presence of extrahepatic metastasis	3
Large and multiple tumors	2
Emergency surgery for primary tumor	2
Surgical procedures
Pure laparoscopic liver resection	26	(60.5%)
HALS	9	(20.9%)
Laparoscopy-assisted liver resection	8	(18.6%)
Recurrence in the remnant liver	16/43	(37.2%)
Repeat hepatectomy	6/16	(37.5%)
Repeat hepatectomy underwent LLH	3/6	(50.0%)

HALS, hand assist laparoscopic surgery;

LLH, laparoscopic liver resection; mFOLFOX6, modified FOLFOX6.